X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4123) 4123
Publication (601) 601
Newsletter (115) 115
Book Review (75) 75
Newspaper Article (10) 10
Book Chapter (9) 9
Magazine Article (9) 9
Conference Proceeding (3) 3
Data Set (3) 3
Trade Publication Article (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bortezomib (3801) 3801
humans (3227) 3227
index medicus (2671) 2671
oncology (1749) 1749
multiple myeloma (1695) 1695
male (1687) 1687
female (1637) 1637
multiple myeloma - drug therapy (1588) 1588
hematology (1452) 1452
middle aged (1397) 1397
aged (1334) 1334
boronic acids - administration & dosage (1237) 1237
pyrazines - administration & dosage (1234) 1234
antineoplastic combined chemotherapy protocols - therapeutic use (1217) 1217
treatment outcome (940) 940
adult (914) 914
cancer (765) 765
dexamethasone (745) 745
dexamethasone - administration & dosage (734) 734
therapy (670) 670
chemotherapy (647) 647
antineoplastic agents - therapeutic use (626) 626
animals (620) 620
care and treatment (617) 617
thalidomide - administration & dosage (601) 601
apoptosis (581) 581
boronic acids - therapeutic use (575) 575
pyrazines - therapeutic use (568) 568
research (560) 560
drug therapy (556) 556
aged, 80 and over (523) 523
dosage and administration (522) 522
antineoplastic agents - administration & dosage (520) 520
lenalidomide (516) 516
thalidomide (506) 506
multiple-myeloma (502) 502
thalidomide - analogs & derivatives (502) 502
antineoplastic combined chemotherapy protocols - adverse effects (496) 496
stem-cell transplantation (495) 495
multiple myeloma - pathology (481) 481
proteasome inhibitors (472) 472
boronic acids - adverse effects (471) 471
pyrazines - adverse effects (469) 469
survival (457) 457
cell line, tumor (449) 449
transplantation (435) 435
multiple myeloma - mortality (414) 414
boronic acids - pharmacology (403) 403
pyrazines - pharmacology (397) 397
bortezomib - administration & dosage (390) 390
mice (386) 386
antineoplastic agents - pharmacology (380) 380
antineoplastic agents - adverse effects (360) 360
apoptosis - drug effects (356) 356
antineoplastic combined chemotherapy protocols - administration & dosage (353) 353
recurrence (352) 352
combination (348) 348
disease-free survival (343) 343
multiple myeloma - therapy (339) 339
article (331) 331
health aspects (324) 324
prognosis (322) 322
pharmacology & pharmacy (321) 321
trial (311) 311
dose-response relationship, drug (304) 304
drug administration schedule (299) 299
proteasome inhibitor bortezomib (291) 291
hemic and lymphatic diseases (287) 287
analysis (284) 284
retrospective studies (279) 279
stem cells (277) 277
medicine & public health (273) 273
melphalan (267) 267
survival analysis (260) 260
patients (259) 259
clinical trials (257) 257
nf-kappa-b (254) 254
melphalan - administration & dosage (253) 253
transplantation, autologous (248) 248
hematology, oncology and palliative medicine (247) 247
patient outcomes (245) 245
proteins (243) 243
proteasome inhibitor (242) 242
multiple myeloma - complications (240) 240
multiple myeloma - diagnosis (235) 235
follow-up studies (228) 228
drug synergism (227) 227
risk factors (226) 226
thalidomide - therapeutic use (225) 225
cyclophosphamide (224) 224
abridged index medicus (221) 221
drug resistance, neoplasm (220) 220
cyclophosphamide - administration & dosage (219) 219
myeloma (217) 217
complications and side effects (215) 215
survival rate (215) 215
cells (213) 213
doxorubicin - administration & dosage (212) 212
remission induction (211) 211
medical research (210) 210
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4073) 4073
Japanese (60) 60
Chinese (51) 51
French (26) 26
Russian (13) 13
German (11) 11
Czech (10) 10
Spanish (7) 7
Hungarian (6) 6
Polish (4) 4
Italian (2) 2
Korean (2) 2
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 08/2015, Volume 126, Issue 6, pp. 721 - 732
Waldenstrom macroglobulinemia (WM) is a B-cell neoplasm manifested by the accumulation of clonal immunoglobulin (Ig)M-secreting lymphoplasmacytic cells. MYD88... 
CONSENSUS PANEL RECOMMENDATIONS | 2ND INTERNATIONAL WORKSHOP | L265P SOMATIC MUTATION | MULTIPLE-MYELOMA | RITUXIMAB THERAPY | IMMUNOGLOBULIN-M | MYD88 L265P | LYMPHOPROLIFERATIVE DISORDERS | LYMPHOPLASMACYTIC CELLS | INHIBITOR EVEROLIMUS | HEMATOLOGY | Cyclophosphamide - administration & dosage | Nitrogen Mustard Compounds - administration & dosage | Waldenstrom Macroglobulinemia - therapy | Humans | Middle Aged | Pyrazines - administration & dosage | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Transplantation, Autologous | Molecular Targeted Therapy | Waldenstrom Macroglobulinemia - pathology | Adult | Receptors, CXCR4 - genetics | B-Lymphocytes - pathology | Boronic Acids - administration & dosage | Everolimus | B-Lymphocytes - metabolism | Waldenstrom Macroglobulinemia - diagnosis | Immunoglobulin M - genetics | Gene Expression | Genetic Predisposition to Disease | Sirolimus - analogs & derivatives | Bortezomib | Pyrimidines - administration & dosage | Myeloid Differentiation Factor 88 - genetics | Antineoplastic Combined Chemotherapy Protocols | Hematopoietic Stem Cell Transplantation | Rituximab | Vidarabine - analogs & derivatives | Cladribine - administration & dosage | Plasmapheresis | Receptors, CXCR4 - metabolism | B-Lymphocytes - drug effects | Sirolimus - administration & dosage | Pyrazoles - administration & dosage | Bendamustine Hydrochloride | Aged | Oligopeptides - administration & dosage | Vidarabine - administration & dosage | Myeloid Differentiation Factor 88 - metabolism | Waldenstrom Macroglobulinemia - genetics
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 10, pp. 934 - 941
Journal Article
Blood, ISSN 0006-4971, 07/2012, Volume 120, Issue 1, pp. 9 - 19
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1195 - 1206
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2011, Volume 29, Issue 6, pp. 690 - 697
Journal Article
British Journal of Haematology, ISSN 0007-1048, 07/2007, Volume 138, Issue 2, pp. 176 - 185
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 2014, Volume 106, Issue 8, pp. dju170 - dju170
This sixteenth biannual report of the Cochrane Haematological Malignancies Group highlights recently published randomized controlled trials (RCTs) in the field... 
SURVIVAL | OUTCOMES | ONCOLOGY | STEM-CELL TRANSPLANTATION | CHOP PLUS RITUXIMAB | Hematologic Neoplasms - therapy | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymphoma, Follicular - drug therapy | Primary Myelofibrosis | Nitrogen Mustard Compounds - administration & dosage | Humans | Pyrazines - administration & dosage | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | Melphalan - adverse effects | Vincristine - administration & dosage | Boronic Acids - administration & dosage | Carmustine - adverse effects | Doxorubicin - administration & dosage | Lymphoma, Non-Hodgkin - drug therapy | Prednisone - administration & dosage | Bortezomib | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Etoposide - administration & dosage | Nitrogen Mustard Compounds - adverse effects | Cytarabine - administration & dosage | Randomized Controlled Trials as Topic | Melphalan - administration & dosage | Pyrazoles - administration & dosage | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 874 - 885
Summary Background Relapsed multiple myeloma has no standard treatment, and the role of autologous stem-cell transplantation (ASCT) has not been fully defined.... 
Hematology, Oncology and Palliative Medicine | MAINTENANCE | SUPERIORITY | BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE | IMPACT | METAANALYSIS | ONCOLOGY | CLINICAL-TRIALS | LENALIDOMIDE | SALVAGE THERAPY | INDUCTION | MARROW TRANSPLANTATION | Recurrence | Cyclophosphamide - administration & dosage | Peripheral Nervous System Diseases - chemically induced | Consolidation Chemotherapy - methods | Humans | Middle Aged | Pyrazines - administration & dosage | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Antineoplastic Agents, Alkylating - administration & dosage | Cyclophosphamide - adverse effects | Multiple Myeloma - therapy | Time Factors | Adult | Female | Boronic Acids - administration & dosage | Neutropenia - chemically induced | Doxorubicin - administration & dosage | Bortezomib | Dexamethasone - administration & dosage | Proportional Hazards Models | Thrombocytopenia - chemically induced | Disease Progression | Induction Chemotherapy - adverse effects | Retreatment | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged | Multiple Myeloma - genetics | Stem Cell Transplantation - adverse effects | Care and treatment | Relapse | Multiple myeloma | Clinical trials | Transplantation | Diseases | Cyclophosphamide | Chemotherapy | Hospitals | Stem cells | Dosage and administration | Product development | Cancer
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2009, Volume 15, Issue 6, pp. 718 - 723
Lenalidomide is an agent that has shown great activity in patients with multiple myeloma (MM). However, studies have suggested that this drug negatively... 
Hematology, Oncology and Palliative Medicine | Myeloma | Stem cell mobilization | Autotransplant | COMBINATION THERAPY | NEWLY-DIAGNOSED MYELOMA | PHASE-2 | THALIDOMIDE | BORTEZOMIB | IMMUNOLOGY | CHEMOTHERAPY | TRANSPLANTATION | PLUS DEXAMETHASONE | REFRACTORY MYELOMA | HEMATOLOGY | MELPHALAN | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hematopoietic Stem Cell Mobilization - methods | Humans | Middle Aged | Heterocyclic Compounds - pharmacology | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Recombinant Proteins | Filgrastim | Thalidomide - analogs & derivatives | Angiogenesis Inhibitors - administration & dosage | Multiple Myeloma - drug therapy | Granulocyte Colony-Stimulating Factor - antagonists & inhibitors | Antineoplastic Agents - adverse effects | Treatment Failure | Angiogenesis Inhibitors - therapeutic use | Vincristine - administration & dosage | Adult | Female | Antineoplastic Agents - pharmacology | Retrospective Studies | Angiogenesis Inhibitors - adverse effects | Multiple Myeloma - surgery | Bone Marrow - drug effects | Doxorubicin - administration & dosage | Multiple Myeloma - blood | Thalidomide - adverse effects | Ifosfamide - pharmacology | Dexamethasone - administration & dosage | Heterocyclic Compounds - administration & dosage | Risk Factors | Etoposide - pharmacology | Etoposide - administration & dosage | Combined Modality Therapy | Thalidomide - administration & dosage | Granulocyte Colony-Stimulating Factor - pharmacology | Leukapheresis | Ifosfamide - administration & dosage | Cyclophosphamide - pharmacology | Aged | Multiple Myeloma - radiotherapy | Thalidomide - therapeutic use | Peripheral Blood Stem Cell Transplantation | Granulocyte Colony-Stimulating Factor - administration & dosage | Chemotherapy | Care and treatment | Granulocyte colony-stimulating factor | Analysis | Multiple myeloma | Stem cells | Transplantation | Angiogenesis inhibitors | Cancer | Index Medicus
Journal Article
by Robak, Tadeusz and Jin, Jie and Pylypenko, Halyna and Verhoef, Gregor and Siritanaratkul, Noppadol and Drach, Johannes and Raderer, Markus and Mayer, Jiri and Pereira, Juliana and Tumyan, Gayane and Okamoto, Rumiko and Nakahara, Susumu and Hu, Peter and Appiani, Carlos and Nemat, Sepideh and Cavalli, Franco and Van Hoof, Achiel and Sheliga, Adriana and Teixeira, Adriana and Tomita, Akihiro and Rocafiguera, Albert Oriol and Suvorov, Alexander and Kuzmin, Alexy and Khojasteh, Ali and Mezlini, Amel and Golenkov, Anatoly and Bosly, Andre and Belch, Andrew and Van De Velde, Ann and Illes, Árpád and Mukhopadhyay, Ashis and Meddeb, Balkis and De Prijck, Bernard and Garichochea, Bernardo and Undar, Bulent and Gabarrón, Caballero and Cao, Carmen and Souza, Carmino and Farber, Charles and Won Suh, Cheol and Burcoveanu, Cristina Ileana and Cebotaru, Cristina Ligia and Truica, Cristina-Ligia and Maruyama, Dai and Belada, David and Ben Yehuda, Dina and Udovitsa, Dmitry and Dolores and Morra, Enrica and Späth-Schwalbe, Ernst and Gonzalez-Barca, Eva and Osmanov, Evgenii and Capote, Francisco Javier and Offner, Fritz and Cardenas, Galvez and Heß, Georg and Manikhas, Georgii and Babu, Govind and Rekhtman, Grigoriy and Rossi, Guiseppe and Marques, Herlander and Marques, Margarida and Bumbea, Horia and Wang, Zhao and Wang, Huaqing and Huang, Huiqiang and Choi, Ilseung and Bulavina, Irina and Lysenko, Irina and Avivi, Irit and Kryachok, Iryna and Zaucha, Jan Maciej and Novak, Jan and Díaz, Joaquín and Demeter, Judit and Alexeeva, Julia and Zhu, Jun and Vilchevskaya, Kateryna and Ishizawa, Kenichi and Mauricio, Kenny and Tobinai, Kensei and Ando, Kiyoshi and Abdulkadryrov, Kudrat and Shih, Lee-Yung and Kuzina, Lyudmila and Gumus, Mahmut and De Wit, Maike and Capra, Marcelo and Golubeva, Marina and Ojeda-Uribe, Mario and Kyselyova, Maryna and Taniwaki, Masafumi and Federico, Massimo and Crump, Michael and Baccarani, Michele and Ogura, Michinori and Egyed, Miklós and Udvardy, Miklos and Kurosawa, Mitsutoshi and Uike, Naokuni and ... and LYM-3002 investigators
The Lancet Oncology, ISSN 1470-2045, 11/2018, Volume 19, Issue 11, pp. 1449 - 1458
Journal Article